Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

20 Solvay Global Annual Report 2005 Neuroscience Fluvoxamine is the fi rst specialty approved for treating social anxiety disorder in Japan In October 2005 Meiji Seika Kaisha Ltd. (Tokyo) and Solvay Seiyaku K. K. (Tokyo) received approval from the Japanese Health Ministry for a new indication for fl uvoxamine, for the treatment of social anxiety disorder. This drug, developed in Japan by Meiji Seika and Solvay Seiyaku, was the fi rst SSRI (selective serotonin uptake inhibitor) launched on the Japanese market, in 1999. It is marketed as DEPROMEL ® by Meiji Seika and as LUVOX ® by Astellas Pharma Inc., Solvay Seiyaku’s designated distributor, for treating depression and depressive states, and obsessive compulsive disorder. Social anxiety disorder patients suffer from excessive anxiety when required to meet other people, express their opinion, telephone in front of others, eat in public, etc. The anxiety leads them to avoid such situations, producing serious problems in their daily lives. Fluvoxamine should improve these patients’ quality of life by eliminating the fear and anxiety. DUODOPA ® for treating late-stage Parkinson’s Since September 2005 Solvay Pharmaceuticals has been marketing DUODOPA ® for treating patients with late stage Parkinson’s disease in 12 new European countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal and Spain. Solvay Pharmaceuticals already had approvals in Sweden and Norway and is also launching the drug in the United Kingdom. DUODOPA ® entered Solvay’s product portfolio when it acquired Swedish pharmaceuticals company Neopharma AB in early 2005. DUODOPA ® is a new and unique treatment based on a combination of levodopa and carbidopa dispersed in a viscous gel. Using a portable pump controlled by the patient via a microprocessor, the medication is administered permanently by a tube directly to the upper part of the small intestine, where it is rapidly absorbed. Parkinson’s disease affects over 1.3 million patients in the major countries. It is the second most prevalent neurodegenerative disease after Alzheimer’s. Pharmaceuticals Sector Apart from DUODOPA ® , Solvay’s R&D department is working to develop promising compounds for treating early stage Parkinson’s. These include the SLV308 compound, which is now at clinical phase III. Bifeprunox: results of phase III clinical trials among schizophrenic patients have led Solvay to revise its European registration plans In November 2005 Solvay Pharmaceuticals and H. Lundbeck A/S announced additional phase III comparative clinical trials in response to European Union expectations. The European registration fi le will therefore be submitted in 2008, two years later than originally scheduled. As announced earlier, Solvay and its US partners, Wyeth Pharmaceuticals, continue to evaluate and analyse the data with a view to applying for registration in the USA in 2006 as scheduled. Bifeprunox is a new compound for treating psychosis and mood disorders like schizophrenia and bipolar disorders. Schizophrenia is a chronic and highly handicapping form of psychosis, characterized by severe mental and perception disorders. The onset of this disorder, which affects around 1% of the world’s population, is generally observed in late adolescence or early adulthood. Flu vaccines Solvay Pharmaceuticals and the world face the threat of bird fl u Solvay Pharmaceuticals is helping the world improve its armoury against a possible pandemic with its new cell culture methodology for vaccine production. The possible proliferation of the H5N1 strain of bird fl u is producing uncertainty and fear amongst the general public and the public authorities. Whilst the virus in its present form is not considered a major threat to human health, many experts agree that it is only a matter of time before it mutates and is transmitted from one human being to another, resulting in a pandemic that can produce many victims. With over 50 years’ experience of vaccine production, Solvay Pharmaceuticals is currently concentrating its full technological resources and knowledge on creating safe and effective vaccines. Over 50 infl uenza experts are researching full-time in our laboratories. In all, more than 300 employees are involved in this project.
“ DUODOPA® entered Solvay’s product portfolio when it acquired Swedish pharmaceuticals company Neopharma AB in early 2005.” Pharmaceuticals 21 Solvay Global Annual Report 2005
Page 1 and 2: Driven by the future Growth, Compet
Page 3 and 4: Highlights January 2005 Solvay fi n
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17 and 18: Specialities Solvay Specialties fro
Page 19 and 20: Key fi gures [EUR million] Pharmace
Page 21 and 22: Cardiometabolic Cardiovascular dise
Page 23: Cardiometabolics Fenofi brate, TRIC
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33 and 34: Initiatives have also been launched
Page 35 and 36: “ The ‘Soil Remediation Reagent
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39 and 40: Innovation “Twin-Sheet Blow Mould
Page 41 and 42: Plastics 37 Solvay Global Annual Re
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76:
The deferred taxes recorded in the
Page 77 and 78:
2005 Millions EUR Acquisitions Disp
Page 79 and 80:
Neopharma On January 19, 2005 the S
Page 81 and 82:
(around 300 persons) with a view to
Page 83 and 84:
In 2005 the impairment tests on goo
Page 85 and 86:
Solvay Group purchased 100% of the
Page 87 and 88:
Post-employment benefi t plans are
Page 89 and 90:
Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?